Recruitment of patients at 10 hospitals including Kyungpook National University Hospital
Shinpoong Pharmaceutical said it expects that the recruitment of patients for the domestic phase 2 clinical trial of’Piramax’, a new coronavirus infection (Corona 19) treatment, will be completed in April next year.
Pyramex (a combination of pyronaridin phosphate and altesunate) is a synthetic drug that has been confirmed to have antiviral and combination effects of each component in a cell test using human lung cell lines.
On May 13th, the phase 2 clinical trial plan was approved by the Ministry of Food and Drug Safety, and patient recruitment is in progress at 10 hospitals including Kyungpook National University Hospital, starting with Korea University Guro Hospital (Professor Kim Woo-joo).
Shinpoong Pharmaceutical planned to complete the phase 2 clinical trial in December of this year, but the recruitment of Piramax clinical patients for mild and moderate patients was delayed because the clinical trial participating institutions are dedicated hospitals mainly focusing on the treatment of severely ill patients.
However, on the 30th, Shinpoong Pharmaceutical said, “As clinical institutions are being expanded, domestic clinical trials are accelerating. In the future, we will try to speed up domestic clinical trials by securing additional clinical institutions with a high hospitalization rate for mild and moderate patients. ”
Through this phase 2 clinical trial, Shinpoong Pharmaceutical plans to confirm the effectiveness of Pyramax, which has already secured safety proven in the clinical and treatment process for malaria, in corona patients, suppressing coronavirus, and improving clinical symptoms.
On the other hand, Shinpoong Pharmaceutical has conducted a phase 2 clinical study to compare the therapeutic effects of a total of four drugs, including local standard symptomatic therapy and Piramax, for 250 African patients with COVID-19 infection in South Africa from last August. In parallel.
Copyright © Farm News Unauthorized reproduction and redistribution prohibited